FORMULATION AND EVALUATION OF MEDICATED CHEWING GUM OF DOLASETRON AS AN ANTIEMETIC AGENT
An attempt has been made to formulate new chewing gum for Dolasetron. The new drug delivery system was obtained, at room temperature conventional pharmaceutical equipment. The resulting chewing gum comprises a gum core combined with fillers, antioxidants, coloring agent and plasticizers, which provide smooth appearance and flexibility during storage and chewing. Drug release from a dosage form is the critical step in drug absorption and bioavailability, thus an experimental work has been designed to evaluate the efficiency of this kind of therapeutic system by verifying its capability to release the drug dose and by assessing the delivery of Dolasetron for bypassing the hepatic first pass effect. Simple diffusion into the medium causes the release of only a small percentage of the drug contained in the medicated chewing gum, while the delivery of the major part of the dose occurs during mastication. In the present study, an attempt has been made to formulate the chewing gum of Dolasetron. Different formulations of chewing gum with varying concentration of plasticizers like glycerol and castor oil were formulated. MCG II formulation was considered to be the best-optimized formula which consists of synthetic gum base (45%), Sorbitol (14.6%), sucrose (46%) etc. which shows first slow release the fast release in the phosphate buffer saline (ph 6.8). The cumulative drug release of MCG II formulation was found to be 99.43 %. From this study, we can conclude that the medicated chewing formulation can be a better choice in the coming years which provides several benefits and also benefits commercially.
2. Shah KR, Mehta TA, Medicated Chewing Gum- A Mobile Oral Drug Delivery System, International Journal of PharmTech Research, 2014; 6:(1)35-48
3. Pathan JA, Nitalikar MM, Formulation and Evaluation of Medicated Chewing Gum Containing Antibacterial Agent. Journal of Current Pharma Research 2014; 4(4):1291-1296
4. John F. Golding. Motion Sickness Susceptibility, Autonomic Neuroscience: Basic and Clinical. 2006; 129:67-76.
5. Neil A. Minton. Volunteer Models for Predicting Antiemetic Activity of 5-HT3 Receptor Antagonists, British Journal of Clinical Pharmacology, 1994; 37:525-530.
6. Ezhumlai K, Rajalakshmi A.N., Ilavarasan P, Sathiyaraj U., Murali Mugundhan R. Medicated Chewing Gum- A Novel Drug Delivery Technique For Systemic and Targeted Drug Delivery, International Journal of Pharmacy & Technology, 2011; 3:725-744.
7. Patel VP. Medicated Chewing Gum: A Review, International Journal of Universal Pharmacy and Life Sciences, 2011; 1:111-128.
8. Savaliya P, Karikar A, Ramana MV. Chewing Gum: A Modern Era of Drug Delivery, international research journal of pharmacy, 2011; 2(10):7-12.
9. Kumar D, Rathi L, Tripathi A, Maddheshiya YP. A Review on Oral Mucosal Drug Delivery System, International Journal of Pharmaceutical Science and Research. 2010; 1:50-56.
10. Surana AS. Chewing Gum: A Friendly Oral Mucosal Drug Delivery System, International Journal of Pharmaceutical Science Review and Research. 2010; 4:68-71.
11. Jain H, Shah M, Shah B, Pasha TY, Medicated Chewing Gum: A Novel Oral Drug Delivery, International Journal of Drug Formulation & Research, 2010; 1:80-96.
12. Venkat Mateti U, Adla N, Rajakannan T, Valakkathala R. Insulin Chewing Gum: Need of the day for Diabetic patients, International Journal of Pharmaceutical Investigation. 2011; 1:131-134.
13. Naik H, Gupta S.Medicated Chewing Gum- Updated Review, International Journal of Pharma Research & Development, 2010; 2:66-76.
14. Pandey S, Goyani M, Devmurari V. Development, In-Vitro Evaluation and Physical Characterization of Medicated Chewing Gum: Chlorohexidine Gluconate, Scholars Research Library, 2009; 2:286-292.
15. Jayachandar Gajendran, Johannes Kraemer, Stig Randers Knudsen. Product Performance Test for Medicated Chewing Gums, Pharmacopeial Forum, 2008; 34:843-847.
16. Catharina Kvist L , Sven-Bo Rje Andersson, Johan Berglund , Bo Wennergren, Susan M. Fors. Equipment for Drug Release Testing of Medicated Chewing Gums, Journal of Pharmaceutical and Biomedical Analysis, 2000; 22:405-411.
17. Gavaskar B, Venkata Ramana D, Y Madhusudan Rao. Medicated Chewing Gum â€“ A Novel Approach to Improve Patient Compliance, International Journal of Research in Pharmaceutical and Biomedical Sciences, 2011; 2;23-32.
18. Madan N, Rathnam A. Chewing Gum for Optimal Health, Chronicles of Young Scientist, 2011; 2:7-10.
19. Patel Y, Shukla A, Saini V, Shrimal N, Sharma P. Chewing Gum as a Drug Delivery System, International Journal of Pharmaceutical Sciences and Research, 2010; 2:748-757.
20. Andrew PLR. Bhandari P,. The 5- Hydroxytrytryptamin Receptor Antagonist as Antiementis: Practical Evolution and Mechanism at Action, European Journal of cancer. 1990; 29:511-516.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).